Genmab | GEN - DEBITO





DEBITO Cambiamento Data
Agios Pharmaceuticals USD 35.74M 4.46M 2026-03
Almirall EUR 342.86M 61.94M 2025-12
Amarin USD 0 0 2025-03
Amgen USD 57.32B 2.72B 2026-03
argenx SE USD 47M 160K 2026-06
AstraZeneca USD 32.24B 1.68B 2026-06
Bayer EUR 36.45B 2.93B 2025-12
BioMarin Pharmaceutical USD 4.2B 2.76B 2026-06
Demant DKK 20.99B 4.81B 2025-12
Exelixis USD 162.2M 3.73M 2026-09
Fresenius Medical Care EUR 10.96B 66.06M 2026-06
Genmab DKK 5.35B 5.2B 2026-03
GlaxoSmithKline GBP 18.24B 818M 2026-06
GN Store Nord DKK 9.96B 855M 2026-03
GRIFOLS EUR 8.52B 1.15B 2026-06
Hikma Pharmaceutical USD 1.6B 46M 2025-12
Insmed USD 544.86M 180.93M 2026-09
Lakefront Biotherapeutics EUR 6.44M 480K 2026-03
Lonza CHF 4.71B 915M 2024-12
Merck EUR 12.04B 86M 2026-03
Novartis USD 49.01B 2.02B 2026-06
Regeneron Pharmaceuticals USD 2.71B 400K 2026-06
Roche Holding CHF 33.03B 1.41B 2025-06
Sanofi EUR 23.58B 3.56B 2026-06
UCB EUR 3.03B 12M 2024-12